HEXYLOXY TRIMETHYLPHENOL (also known as 1-O-Hexyl-2,3,5-trimethylhydroquinone or HTHQ) originally has been found to have two types of activities: anti-oxidant anti-lipid-peroxidative. In addition, experiments on rodents have shown that HTHQ possessed chemopreventive effects against heterocyclic amine-induced carcinogenesis. It is known that HTHQ directly reacts with reactive oxygen species (ROS) and scavenging them to form more stable free radicals. Recently published article has shown that HTHQ could be a promising adjuvant therapeutic agent against L-dopa-induced neurotoxicity. This effect has been achieved by both inhibiting the initiation of ROS formation and modulating the activity of ERK1/2.